Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience

被引：32

作者：

Stingeni, L. ^{[1
]}

Bianchi, L. ^{[1
,23
]}

Antonelli, E. ^{[1
]}

Caroppo, E. S. ^{[1
]}

Ferrucci, S. M. ^{[2
]}

Ortoncelli, M. ^{[3
]}

Fabbrocini, G. ^{[4
]}

Nettis, E. ^{[5
]}

Schena, D. ^{[6
]}

Napolitano, M. ^{[7
]}

Gola, M. ^{[8
]}

Bonzano, L. ^{[9
]}

Rossi, M. ^{[10
]}

Fortina, A. Belloni ^{[11
]}

Balato, A. ^{[12
]}

Peris, K. ^{[13
]}

Foti, C. ^{[14
]}

Guarneri, F. ^{[15
]}

Romanelli, M. ^{[16
]}

Patruno, C. ^{[17
]}

Savoia, P. ^{[18
]}

Fargnoli, M. C. ^{[19
]}

Russo, F. ^{[20
]}

Errichetti, E. ^{[21
]}

Bianchelli, T. ^{[22
]}

Bianchi, L. ^{[1
,23
]}

Pellacani, G. ^{[24
]}

Feliciani, C. ^{[25
]}

Offidani, A. ^{[26
]}

Corazza, M. ^{[27
]}

Micali, G. ^{[28
]}

Milanesi, N. ^{[29
]}

Malara, G. ^{[30
]}

Chiricozzi, A. ^{[13
]}

Tramontana, M. ^{[1
]}

Hansel, K. ^{[1
]}

机构：

[1] Univ Perugia, Dept Med & Surg, Dermatol Sect, Perugia, Italy

[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[3] Univ Turin, Dept Med Sci, Div Dermatol, Turin, Italy

[4] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[5] Univ Bari, Dept Emergency & Organ Transplantat, Allergol & Clin Immunol, Bari, Italy

[6] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy

[7] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy

[8] Univ Florence, Dept Hlth Sci, Unit Allergol & Pediat Dermatol, Florence, Italy

[9] Azienda USL IRCCS Reggio Emilia, Dermatol Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

[10] Univ Brescia, Dept Dermatol, ASST Spedali Civili Brescia, Brescia, Italy

[11] Univ Padua, Dept Med DIMED, Unit Dermatol, Padua, Italy

[12] Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy

[13] Catholic Univ, Inst Dermatol, Rome, Italy

[14] Univ Bari, Dept Biomed Sci & Human Oncol, Sect Dermatol, Bari, Italy

[15] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, Messina, Italy

[16] Univ Pisa, Dermatol Unit, Pisa, Italy

[17] Magna Graecia Univ Catanzaro, Hlth Sci Dept, Sect Dermatol, Catanzaro, Italy

[18] Univ Piemonte Orientale, Dept Hlth Sci, Dermatol Clin, Novara, Italy

[19] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Dermatol, Laquila, Italy

[20] Univ Siena, Dept Clin Surg Med & Neurosci, Sect Dermatol, Siena, Italy

[21] Univ Udine, Inst Dermatol, Dept Med Dame, Udine, Italy

[22] INRCA IRCCS Hosp, Dermatol Unit, Ist Nazl Riposo & Cura Anziani, Ancona, Italy

[23] Univ Tor Vergata, Syst Med Dept, Dermatol Unit, Rome, Italy

[24] Sapienza Univ Rome, Dept Dermatol, Policlin Umberto 1, Rome, Italy

[25] Univ Parma, Dept Clin & Expt Med, Sect Dermatol, Parma, Italy

[26] Polytech Marche Univ, Clin & Mol Sci Dept, Dermatol Clin, Ancona, Italy

[27] Univ Ferrara, Dept Med Sci, Sect Dermatol, Ferrara, Italy

[28] Univ Catania, Dermatol Clin, Catania, Italy

[29] Univ Florence, Dept Surg & Translat Med, Allergol & Occupat Dermatol Unit, Florence, Italy

[30] Grande Osped Metropolitano, Dermatol Unit, Reggio Di Calabria, Italy

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 08期

关键词：

QUALITY-OF-LIFE; CHILDREN; ECZEMA; ASTHMA; ASSOCIATION; DERMATOLOGY; POPULATION; PREVALENCE; DIAGNOSIS;

D O I：

10.1111/jdv.18141

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. Methods Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. Results One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. Conclusions Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.

引用

页码：1292 / 1299

页数：8

共 50 条

[21] Upadacitinib for the treatment of moderate-to-severe atopic dermatitis in real-world clinical practice
Tran, Vanessa
Ross, Gayle
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 11 - 11
[22] Real-world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2-year experience
Fujiwara, Chisako
Uchiyama, Akihiko
Inoue, Yuta
Ishikawa, Mai
Motegi, Sei-ichiro
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (03) : 88 - 93
[23] Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic
Hansel, K.
Patruno, C.
Antonelli, E.
Dal Bello, G.
Napolitano, M.
Fabbrocini, G.
Grieco, T.
Pellacani, G.
Fargnoli, M. C.
Esposito, M.
Piras, V.
Zucca, M.
Girolomoni, G.
Stingeni, L.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (01) : 165 - 167
[24] Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
Mareschal, Adrien
Puzenat, Eve
Aubin, Francois
ACTA DERMATO-VENEREOLOGICA, 2020, 100 (01)
[25] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, Lisa A.
Thaci, Diamant
Hamilton, Jennifer D.
Graham, Neil M.
Bieber, Thomas
Rocklin, Ross
Ming, Jeffrey E.
Ren, Haobo
Kao, Richard
Simpson, Eric
Ardeleanu, Marius
Weinstein, Steven P.
Pirozzi, Gianluca
Guttman-Yassky, Emma
Suarez-Farinas, Mayte
Hager, Melissa D.
Stahl, Neil
Yancopoulos, George D.
Radin, Allen R.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
[26] Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis
Marcant, P.
Balaye, P.
Merhi, R.
Jendoubi, F.
Nosbaum, A.
Raison-Peyron, N.
Du-Thanh, A.
Lasek, A.
Ferrier le Bouedec, M. -C.
Tetart, F.
Valois, A.
Barbarot, S.
Soria, A.
Jachiet, M.
Staumont-Salle, D.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (06) : E394 - E396
[27] Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China
Song, Xiaoting
Liu, Bo
Luan, Tingting
Liao, Shuanglu
Tan, Yen
Peng, Chengyue
Zhao, Zuotao
ALLERGY, 2023, 78 (06) : 1696 - 1699
[28] Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab
de Bruin-Weller, M.
Eckert, L.
Simpson, E. L.
Cork, M. J.
Ardeleanu, M.
Chen, Z.
Shumel, B.
Rossi, A. B.
Graham, N. M. H.
Pirozzi, G.
Gadkari, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 116 - 116
[29] Real-life experience with dupilumab in 56 children and adolescents aged 2 to 17 with uncontrolled moderate-to-severe atopic dermatitis
Colonna, Cristiana
Monzani, Nicola A.
Quattri, Eleonora
Montefusco, Francesca
Cavalli, Riccardo
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2024, 159 (06) : 694 - 695
[30] Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study
Yang, Dan-Yang
Li, Li
Lu, Tao
Jing, Wen-Wen
Liu, Xin
Li, Xiao-Li
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (03) : 467 - 472

← 1 2 3 4 5 →